title: The relationship between long-term proton pump inhibitor therapy and skeletal frailty.
abstract: Proton pump inhibitors (PPIs) are a commonly prescribed class of medications. Their use has been associated with an increased rate of fractures, most notably hip fractures. However, there does not seem to be a clear association between PPI use and bone mineral density measurements, assessed by dual X-ray absorptiometry. The mechanism by which PPI use increases the risk of fractures remains unclear. This review will summarize the current evidence on this topic.
authors.affiliation: Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, Canada, arthur.lau@medportal.ca.
authors.forename: Arthur N
authors.initials: AN
authors.lastname: Lau
authors.forename: Michael
authors.initials: M
authors.lastname: Tomizza
authors.forename: Matthew
authors.initials: M
authors.lastname: Wong-Pack
authors.forename: Alexandra
authors.initials: A
authors.lastname: Papaioannou
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Adachi
mesh_terms: D015502:Absorptiometry, Photon; D015519:Bone Density / Q000187:drug effects; D001847:Bone Diseases / Q000139:chemically induced* / Q000453:epidemiology; D050723:Fractures, Bone / Q000453:epidemiology*; D006620:Hip Fractures / Q000453:epidemiology; D006801:Humans; D054328:Proton Pump Inhibitors / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D054328:Proton Pump Inhibitors